NYSE:EBS

Emergent BioSolutions - EBS Stock Forecast, Price & News

$20.99

+0.21 (+1.01%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $20.89
▼
$21.88
50-Day Range: $20.09
▼
$35.80
52-Week Range: $20.06
▼
$55.35

Volume: 519,483 shs
Average Volume: 604,045 shs
Market Capitalization: $1.05 billion

P/E Ratio: 12.42
Dividend Yield: N/A
Price Target: $48.83

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 132.7% Upside
$48.83 Price Target
Short Interest: Bearish
5.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.96
Upright™ Environmental Score
News Sentiment: 0.50
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.63) to $1.76 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

165th out of 1,093 stocks

Pharmaceutical Preparations Industry

62nd out of 547 stocks

3.2

Analyst's Opinion

Consensus Rating
Emergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.83, Emergent BioSolutions has a forecasted upside of 132.7% from its current price of $20.99.
Amount of Analyst Coverage
Emergent BioSolutions has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.04% of the float of Emergent BioSolutions has been sold short.
Short Interest Ratio / Days to Cover
Emergent BioSolutions has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Emergent BioSolutions has recently increased by 5.13%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Emergent BioSolutions does not currently pay a dividend.
Dividend Growth
Emergent BioSolutions does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Emergent BioSolutions has received a 72.53% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cholera vaccines", "Smallpox vaccines", and "Typhoid vaccines" products. See details.
Environmental Sustainability
The Environmental Impact score for Emergent BioSolutions is -1.96.

1.9

News and Social Media Coverage

News Sentiment
Emergent BioSolutions has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Emergent BioSolutions this week, compared to 2 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 2 reddit mentions for Emergent BioSolutions this week, compared to 0 mentions on an average week.
Search Interest
Only 1 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.10% of the stock of Emergent BioSolutions is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
81.54% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Emergent BioSolutions are expected to grow in the coming year, from ($0.63) to $1.76 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Emergent BioSolutions is 12.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.87.
Price to Earnings Ratio vs. Sector
The P/E ratio of Emergent BioSolutions is 12.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 103.90.
Price to Book Value per Share Ratio
Emergent BioSolutions has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

September 30, 2022 | americanbankingnews.com

Emergent BioSolutions (NYSE:EBS) Shares Gap Up to $20.53

September 27, 2022 | finance.yahoo.com

Durham pharma nets $238M for smallpox drug with more payouts lined up

October 1, 2022 | Legacy Research (Affiliate) (Ad)

The 3-Stock Retirement Blueprint

When most folks think about making money through the markets, they think “buy and hold.” They think “diversification.” And they think about investing in things like index funds. But one man has a different approach… It’s called the “3-Stock Retirement Blueprint.”

September 26, 2022 | finance.yahoo.com

Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

September 26, 2022 | finance.yahoo.com

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

September 6, 2022 | finance.yahoo.com

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

September 2, 2022 | nasdaq.com

Emergent Biosolutions Inc Shares Near 52-Week Low - Market Mover

August 31, 2022 | nasdaq.com

Emergent Biosolutions Inc Shares Close in on 52-Week Low - Market Mover

October 1, 2022 | Legacy Research (Affiliate) (Ad)

Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast

He predicted the 2020 crash a month before it happened…He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution.

August 31, 2022 | finance.yahoo.com

Emergent Biosolutions (EBS) Down 20% Since Last Earnings Report: Can It Rebound?

August 30, 2022 | nasdaq.com

Interesting EBS Put And Call Options For October 21st

August 29, 2022 | apnews.com

Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

August 25, 2022 | seekingalpha.com

Emergent BioSolutions: Now Long Through Sale Of October Put Spreads

August 24, 2022 | nasdaq.com

Emergent Biosolutions Inc Shares Approach 52-Week Low - Market Mover

August 23, 2022 | seekingalpha.com

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

August 15, 2022 | finance.yahoo.com

FDA Issues Warning Letter For Emergent Bio's Manufacturing Facility

August 9, 2022 | finance.yahoo.com

Emergent BioSolutions Inc.'s (NYSE:EBS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

August 3, 2022 | nasdaq.com

These 4 Measures Indicate That Emergent BioSolutions (NYSE:EBS) Is Using Debt Extensively

August 2, 2022 | finance.yahoo.com

Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus

August 2, 2022 | finance.yahoo.com

Emergent BioSolutions (EBS) Q2 2022 Earnings Call Transcript

August 1, 2022 | seekingalpha.com

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q2 2022 Results - Earnings Call Transcript

August 1, 2022 | finance.yahoo.com

Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue Estimates

August 1, 2022 | finance.yahoo.com

Emergent BioSolutions in ‘early innings’ of shift away from Covid-19 vaccine work

August 1, 2022 | finance.yahoo.com

Emergent BioSolutions Reports Financial Results for Second Quarter 2022

July 26, 2022 | seekingalpha.com

Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic

July 26, 2022 | nasdaq.com

First Week of March 2023 Options Trading For Emergent BioSolutions (EBS)

July 26, 2022 | finance.yahoo.com

4 Things to Know About Company Making the Monkeypox Vaccine

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Company Calendar

Last Earnings: 8/01/2022
Today: 10/01/2022
Next Earnings (Estimated): 11/03/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NYSE:EBS
CUSIP: 29089Q10
CIK: 1367644
Web: www.emergentbiosolutions.com
Phone: (240) 631-3200
Fax: 301-795-1899
Employees: 2,416
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $48.83
High Stock Price Forecast: $77.00
Low Stock Price Forecast: $29.00
Forecasted Upside/Downside: +132.7%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.69
Trailing P/E Ratio: 12.42
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $230.90 million
Net Margins: 6.02%
Pretax Margin: 8.45%
Return on Equity: 12.22%
Return on Assets: 6.71%

Debt

Debt-to-Equity Ratio: 0.52
Current Ratio: 3.92
Quick Ratio: 2.38

Sales & Book Value

Annual Sales: $1.79 billion
Price / Sales: 0.58
Cash Flow: $8.53 per share
Price / Cash Flow: 2.46
Book Value: $30.09 per share
Price / Book: 0.70

Miscellaneous

Outstanding Shares: 49,860,000
Free Float: 44,327,000
Market Cap: $1.05 billion
Optionable: Optionable
Beta: 1.07

Key Executives

Mr. Robert G. Kramer Sr. (Age 65)
CEO, Pres & Exec. Director
Comp: $1.93M

Mr. Richard S. Lindahl (Age 58)
Exec. VP, CFO & Treasurer
Comp: $858.61k

Mr. Adam R. Havey (Age 51)
Exec. VP & COO
Comp: $843.1k

Mr. Atul Saran (Age 49)
Exec. VP & Chief Strategy and Devel. Officer
Comp: $820.66k

Mr. Robert G. Burrows
VP of Investor Relations

Ms. Jennifer L. Fox
Exec. VP of External Affairs, Gen. Counsel & Corp. Sec.

Ms. Coleen Glessner
Exec. VP of Global Quality and Ethics & Compliance

Ms. Lynn Kieffer
VP of Corp. Communications

Ms. Katherine Strei (Age 60)
Exec. VP of HR & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings or view top-rated stocks.
What is Emergent BioSolutions' stock price forecast for 2022?: 6 brokerages have issued 1 year price targets for Emergent BioSolutions' shares. Their EBS share price forecasts range from $29.00 to $77.00. On average, they anticipate the company's stock price to reach $48.83 in the next year. This suggests a possible upside of 132.7% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.
How have EBS shares performed in 2022?: Emergent BioSolutions' stock was trading at $43.47 at the beginning of 2022. Since then, EBS shares have decreased by 51.7% and is now trading at $20.99.
View the best growth stocks for 2022 here.
Are investors shorting Emergent BioSolutions?: Emergent BioSolutions saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 1,950,000 shares, a decrease of 34.8% from the August 15th total of 2,990,000 shares. Based on an average daily trading volume, of 619,300 shares, the days-to-cover ratio is currently 3.1 days. Approximately 4.8% of the shares of the company are short sold.
View Emergent BioSolutions' Short Interest.
When is Emergent BioSolutions' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our EBS earnings forecast.
How were Emergent BioSolutions' earnings last quarter?: Emergent BioSolutions Inc. (NYSE:EBS) released its earnings results on Monday, August, 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.63 by $1.49. The biopharmaceutical company had revenue of $242.70 million for the quarter, compared to analysts' expectations of $268.77 million. Emergent BioSolutions had a trailing twelve-month return on equity of 12.22% and a net margin of 6.02%. The company's revenue for the quarter was down 38.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.33 earnings per share.

What guidance has Emergent BioSolutions issued on next quarter's earnings?: Emergent BioSolutions issued an update on its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $230.00 million-$270.00 million, compared to the consensus revenue estimate of $301.17 million.
What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?: 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.
What other stocks do shareholders of Emergent BioSolutions own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).
What is Emergent BioSolutions' stock symbol?: Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How do I buy shares of Emergent BioSolutions?: Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Emergent BioSolutions' stock price today?: One share of EBS stock can currently be purchased for approximately $20.99.
How much money does Emergent BioSolutions make?: Emergent BioSolutions (NYSE:EBS) has a market capitalization of $1.05 billion and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $1.69 on an earnings per share basis.
How many employees does Emergent BioSolutions have?: The company employs 2,416 workers across the globe.
How can I contact Emergent BioSolutions?: Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Emergent BioSolutions - EBS Stock Forecast, Price & News

Emergent BioSolutions MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Social Mentions This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Emergent BioSolutions (NYSE:EBS) Stock

EBS Stock News Headlines

EBS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

EBS Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™